Opko Health, Inc.
- Country
- 🇨🇱Chile
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 3.9K
- Market Cap
- -
- Website
- http://www.opko.com
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT03406377
- Locations
- 🇺🇸
National Research Institute - Huntington Park, Huntington Park, California, United States
🇺🇸National Research Institute - Wilshire, Los Angeles, California, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Hialeah, Florida, United States
Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03355651
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT03297398
- Locations
- 🇺🇸
APF Research, LLC, Miami, Florida, United States
🇺🇸Meridien Research - Brooksville, Spring Hill, Florida, United States
🇺🇸Florida Urology Partners, Tampa, Florida, United States
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT02968004
- Locations
- 🇮🇳
Manipal Hospital, Bengaluru, Karnataka, India
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
🇺🇸University of Massachusettes, Worcester, Massachusetts, United States
A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02919800
- Locations
- 🇮🇱
TASMC, Tel-Aviv, Israel
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02692781
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02500316
- Locations
- 🇧🇾
2DKB, Minsk, Belarus
🇺🇦Odessa Regional Children'S Clinical Hospital, Odessa, Ukraine
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02418793
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02418767
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT02282813